{"id":"avastin-paclitaxel-carboplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab (Avastin) is a monoclonal antibody that blocks VEGF signaling to prevent new blood vessel formation in tumors, starving them of nutrients. Paclitaxel is a microtubule stabilizer that disrupts cell division, while carboplatin is a platinum-based alkylating agent that damages DNA. Together, this triplet regimen combines anti-angiogenic and cytotoxic mechanisms for enhanced anti-tumor activity.","oneSentence":"This combination uses bevacizumab to inhibit tumor angiogenesis while paclitaxel and carboplatin work as chemotherapy agents to kill cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:14.015Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic non-small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT06843447","phase":"PHASE1, PHASE2","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-15","conditions":"Ovarian Cancer Recurrent","enrollment":280},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT03635567","phase":"PHASE3","title":"Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-25","conditions":"Cervical Cancer","enrollment":617},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT03740165","phase":"PHASE3","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-18","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":1367},{"nctId":"NCT05446870","phase":"PHASE2","title":"Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-25","conditions":"High-grade Serous Ovarian Carcinoma, Ovarian Carcinoma","enrollment":160},{"nctId":"NCT03275506","phase":"PHASE2","title":"PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2018-02-26","conditions":"Ovarian Cancer Stage IV","enrollment":91},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT03390686","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prestige Biopharma Limited","startDate":"2019-11-15","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":650},{"nctId":"NCT01220154","phase":"PHASE1","title":"Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer","status":"COMPLETED","sponsor":"David O'Malley","startDate":"2011-04-28","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":9},{"nctId":"NCT02754882","phase":"PHASE3","title":"A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2016-07-05","conditions":"Lung Cancer, Non-small Cell Lung Cancer","enrollment":763},{"nctId":"NCT05654454","phase":"PHASE3","title":"A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Mabscale, LLC","startDate":"2023-05-31","conditions":"Non-Small Cell Lung Cancer","enrollment":620},{"nctId":"NCT01763645","phase":"PHASE3","title":"A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Biocad","startDate":"2012-10","conditions":"Non-small Cell Lung Cancer","enrollment":353},{"nctId":"NCT02039674","phase":"PHASE1, PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-21","conditions":"Non-small Cell Lung Carcinoma","enrollment":267},{"nctId":"NCT04633564","phase":"PHASE3","title":"MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2017-01-21","conditions":"NSCLC Stage IV","enrollment":671},{"nctId":"NCT02810457","phase":"PHASE3","title":"Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Centus Biotherapeutics Limited","startDate":"2016-09-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":731},{"nctId":"NCT05169801","phase":"PHASE3","title":"To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-01-25","conditions":"Non-small Cell Lung Cancer(NSCLC)","enrollment":520},{"nctId":"NCT03329911","phase":"PHASE3","title":"A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2017-10-20","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":651},{"nctId":"NCT03296163","phase":"PHASE3","title":"A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2018-02-06","conditions":"Non-small Cell Lung Cancer","enrollment":627},{"nctId":"NCT04416035","phase":"PHASE3","title":"A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC","status":"UNKNOWN","sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","startDate":"2020-08-17","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer","enrollment":608},{"nctId":"NCT00652119","phase":"PHASE1","title":"Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2008-02","conditions":"Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":46},{"nctId":"NCT03169335","phase":"PHASE3","title":"Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2017-03-28","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":535},{"nctId":"NCT00675259","phase":"PHASE2","title":"Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2008-07","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT03071848","phase":"","title":"A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-04-06","conditions":"Cervical Cancer","enrollment":84},{"nctId":"NCT01219777","phase":"PHASE1","title":"Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \\Bevacizumab for Primary Ovarian","status":"COMPLETED","sponsor":"Ritu Salani","startDate":"2010-09","conditions":"Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer","enrollment":9},{"nctId":"NCT03195569","phase":"","title":"To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2017-03-01","conditions":"Non Small Cell Lung Cancer","enrollment":15},{"nctId":"NCT00874107","phase":"PHASE2","title":"Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"HiberCell, Inc.","startDate":"2009-06","conditions":"Non-Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT02879097","phase":"PHASE3","title":"Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC","status":"UNKNOWN","sponsor":"Cipla BioTec Pvt. Ltd.","startDate":"2016-12","conditions":"Non-Small Cell Lung Carcinoma","enrollment":200},{"nctId":"NCT01426880","phase":"PHASE2, PHASE3","title":"Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2011-08","conditions":"Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS","enrollment":595},{"nctId":"NCT00479674","phase":"PHASE2","title":"Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Duke University","startDate":"2007-05","conditions":"Breast Cancer","enrollment":41},{"nctId":"NCT00777673","phase":"PHASE2","title":"Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.","status":"UNKNOWN","sponsor":"University of Tennessee Cancer Institute","startDate":"2008-10","conditions":"Breast Cancer","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":149,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Avastin®, paclitaxel, carboplatin","genericName":"Avastin®, paclitaxel, carboplatin","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses bevacizumab to inhibit tumor angiogenesis while paclitaxel and carboplatin work as chemotherapy agents to kill cancer cells. Used for Advanced or metastatic non-small cell lung cancer, Ovarian cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}